Royalty Report: Drugs, Biotechnology, Diagnostic – Collection: 5850

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Diagnostic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5850

License Grant
The Foundation grants to Licensee a non-exclusive License in the territory within the Field of Use, without the right to subLicense (except to its Affiliates), to use and breed the Licensed Technology, and to use the Licensed Know-How, under the Mayo Patent Rights, according to the terms of this LSRA.
License Property
Licensed Technology means mice of the Tg 2576 strain of the transgenic mouse model described in Hsiao et al, Correlative Memory Deficils, A-Beta Elevation and Amyloid Plaques in Transgenic.  All reference to the singular shall include the plural and vice-versa.  169 Patent Rights mean U.S. Patent Number 5,455,169, issued October 3, 1995. MAYO believes that dissemination of these transgenic mice to researchers is of potential great benefit to present and future patients having Alzheimer's Disease and other neurodegenerative diseases.

DEVELOPMENT PROGRAMS. means pharmaceutical, biotechnological and diagnostic development programs in the field of Alzheimer's Disease and other central nervous system and neurodegenerative diseases as performed by LICENSEE or its Affiliates.

LICENSED TECHNOLOGY. means (a) mice of the Tg 2576 strain of the transgenic mouse model described in Hsiao et al, Correlative Memory Deficils, A-Beta Elevation and Amyloid Plaques in Transgenic Mice, as published in Science on October 4, 1996, or in a U.S. continuation-in-part patent application, filed June 17, 1996, Serial No. 08/664,872 (the “CIP Application”), which mice are (1) progeny of a cross of a Tg2576 N2 male with a C57B6SJL female or (2) the progeny of a cross between (Tg2576 N2 x C57B6SJL) male with a C57B6SJL female, (such mice referred to herein as” Stock”); (b) progeny of the Stock; and (c) certain transgenic mice that may result from the Sponsored Research Activities.

IPSCIO Record ID: 6887

License Grant
Mindset acquired from the Licensor, a non-exclusive License to use certain transgenic mice as models for Alzheimer’s disease and was obligated to pay the Licensor a royalty on any net revenue that Mindset received from the sale or licensing of a drug product for Alzheimer’s disease in which the transgenic mice were used for research purposes.

Pursuant to the Assignment that the Licensee executed with the University of South Alabama Medical Science Foundation , the Licensee agreed to assume Mindset’s obligations to pay royalties to the Licensor. We have not received any net revenue that would trigger a payment obligation to the Licensor.

Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 6138

License Grant
The Licensee has the exclusive License to the rights to the NTP testing technology, which measures the level of a brain protein called neural thread protein (NTP), and which is elevated early in Alzheimer's disease, effective in 1997.   University and the Licensor are part of a sponsored research and licensing agreement, under which the Licensee sponsored the research of the principal investigations into the use of neural thread protein, its antibodies or genes for diagnostic or therapeutic purposes. The Licensee also paid the patent costs for the patent applications filed arising out of this research. In return under the agreement, the licensee received an exclusive worldwide license of the patents to sell products and to use processes encompassed by them.
License Property
The Licensor have discovered Neural Thread Protein, and developed antibodies, probes, and other reagents, patents, and information associated with this protein and are interested in the development of new diagnostic strategies for Alzheimer's Disease and other neurodegenerative diseases ('TECHNOLOGY');

The term 'PATENT RIGHT' shall mean: (a) (i) the United States Patent Application Serial No. 07/287,207 filed December 20, 1988 entitled 'Method of Detecting Neurological Disease or Dysfunction,' (ii) the United States CIP Patent Application Serial No. 07/451,975 filed on December 20, 1989, (iii) the United States Patent Application Serial Number 08/055,778 filed May 3, 1993 as a file wrapper continuation, and, (iv) the United States Patent Application Serial Number to be assigned, filed June 6, 1995 as a divisional application,

b) (i) the United States Patent Application Serial No. 08/050,559 filed on April 20, 1993 entitled 'Neural Thread Protein Gene Expression and Detection of Alzheimer's Disease, ' (ii) the United States CIP Patent Application Serial No. 08/230,139 filed on April 20, 1994, (iii) the United States CIP Patent Application 08/340,426 filed on November 14, 1994, (iv) the United States Patent Application Serial No. 08/454,557 filed on May 30, 1995 as a divisional application, and (v) the United States Patent Application Serial No. 08/450,673 filed on May 30, 1995 as a divisional application;

Field of Use
The term 'FIELD OF RESEARCH' shall mean research pertaining to the use of any form of neural thread protein, its antibodies, and any cDNAs or genes or genomic fragments coding for neural thread protein, for diagnostic purposes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.